blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3237379

EP3237379 - PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.02.2023
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  04.03.2022
FormerGrant of patent is intended
Status updated on  11.10.2021
FormerExamination is in progress
Status updated on  09.09.2021
FormerGrant of patent is intended
Status updated on  29.04.2021
FormerExamination is in progress
Status updated on  19.03.2021
FormerGrant of patent is intended
Status updated on  23.11.2020
FormerExamination is in progress
Status updated on  10.04.2019
FormerRequest for examination was made
Status updated on  29.09.2017
FormerThe international publication has been made
Status updated on  19.07.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Convergence Pharmaceuticals Limited
70 Norden Road
Maidenhead
Berkshire SL6 4AY / GB
[2022/14]
Former [2017/44]For all designated states
Convergence Pharmaceuticals Limited
70 Norden Road
Maidenhead
Berkshire SL6 4AY / GB
Inventor(s)01 / MACPHERSON, David
c/o Convergence Pharmaceuticals Limited
Maia Building
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT / GB
02 / WITTY, David
c/o Convergence Pharmaceuticals Limited
Maia Building
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT / GB
03 / GIBLIN, Gerard
c/o Convergence Pharmaceuticals Limited
Maia Building
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT / GB
04 / WILLIAMS, Michael
c/o Convergence Pharmaceuticals Limited
Maia Building
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT / GB
05 / WALKER, Donald
c/o Biogen
115 Broadway Street
Cambridge, Massachusetts 02142 / US
06 / KIESMAN, William
c/o Biogen
115 Broadway Street
Cambridge, Massachusetts 02142 / US
07 / MACK, Tamera
c/o Biogen
115 Broadway Street
Cambridge, Massachusetts 02142 / US
 [2017/44]
Representative(s)Mathys & Squire
The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2022/14]Miller, David James, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
Former [2017/44]Gibson, Mark
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
Application number, filing date15817522.423.12.2015
[2017/44]
WO2015GB54140
Priority number, dateGB2014002310723.12.2014         Original published format: GB 201423107
[2017/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016102967
Date:30.06.2016
Language:EN
[2016/26]
Type: A1 Application with search report 
No.:EP3237379
Date:01.11.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 30.06.2016 takes the place of the publication of the European patent application.
[2017/44]
Type: B1 Patent specification 
No.:EP3237379
Date:06.04.2022
Language:EN
[2022/14]
Search report(s)International search report - published on:EP30.06.2016
ClassificationIPC:C07D207/16
[2017/44]
CPC:
C07D207/16 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/44]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN ZUR HERSTELLUNG VON ALPHA-CARBOXAMID-PYRROLIDINDERIVATEN[2020/50]
English:PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES[2017/44]
French:PROCÉDÉ POUR LA PRÉPARATION DE DÉRIVÉS DE PYRROLIDINE ALPHA-CARBOXAMIDE[2020/50]
Former [2017/44]VERFAHREN ZUR HERSTELLUNG VON ALPHA-CARBOXAMID-PYRROLIDIN-DERIVATEN
Former [2017/44]PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS D'ALPHA-CARBOXAMIDE DE PYRROLIDINE
Entry into regional phase18.07.2017National basic fee paid 
18.07.2017Designation fee(s) paid 
18.07.2017Examination fee paid 
Examination procedure18.07.2017Examination requested  [2017/44]
18.07.2017Date on which the examining division has become responsible
29.03.2018Amendment by applicant (claims and/or description)
15.04.2019Despatch of a communication from the examining division (Time limit: M04)
19.08.2019Reply to a communication from the examining division
24.11.2020Communication of intention to grant the patent
17.03.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.04.2021Communication of intention to grant the patent
08.09.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
27.10.2021Communication of intention to grant the patent
25.02.2022Fee for grant paid
25.02.2022Fee for publishing/printing paid
25.02.2022Receipt of the translation of the claim(s)
Opposition(s)10.01.2023No opposition filed within time limit [2023/11]
Fees paidRenewal fee
28.11.2017Renewal fee patent year 03
18.12.2018Renewal fee patent year 04
13.12.2019Renewal fee patent year 05
14.12.2020Renewal fee patent year 06
17.12.2021Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.12.2015
AL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
MK06.04.2022
MT06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
IE23.12.2022
LU23.12.2022
BE31.12.2022
[2024/41]
Former [2024/29]HU23.12.2015
AL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
MK06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
IE23.12.2022
LU23.12.2022
BE31.12.2022
Former [2024/27]HU23.12.2015
AL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MK06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
IE23.12.2022
LU23.12.2022
BE31.12.2022
Former [2024/21]HU23.12.2015
AL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
IE23.12.2022
LU23.12.2022
BE31.12.2022
Former [2024/18]HU23.12.2015
AL06.04.2022
AT06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
IE23.12.2022
LU23.12.2022
BE31.12.2022
Former [2023/49]AL06.04.2022
AT06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
IE23.12.2022
LU23.12.2022
BE31.12.2022
Former [2023/48]AL06.04.2022
AT06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
IE23.12.2022
LU23.12.2022
Former [2023/38]AL06.04.2022
AT06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
LU23.12.2022
Former [2023/25]AL06.04.2022
AT06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2023/17]AL06.04.2022
AT06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2023/09]AT06.04.2022
CZ06.04.2022
DK06.04.2022
EE06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SE06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2023/07]AT06.04.2022
DK06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RS06.04.2022
SE06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2022/51]AT06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RS06.04.2022
SE06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2022/50]AT06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
PL06.04.2022
RS06.04.2022
SE06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
PT08.08.2022
Former [2022/49]AT06.04.2022
FI06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
NL06.04.2022
SE06.04.2022
BG06.07.2022
NO06.07.2022
GR07.07.2022
PT08.08.2022
Former [2022/47]AT06.04.2022
FI06.04.2022
LT06.04.2022
NL06.04.2022
SE06.04.2022
NO06.07.2022
PT08.08.2022
Former [2022/44]NL06.04.2022
Cited inInternational search[XD]WO2007042239  (GLAXO GROUP LTD [GB], et al) [XD] 26 * the whole document *;
 [A]WO2007042240  (GLAXO GROUP LTD [GB], et al) [A] 1-26* the whole document *;
 [X]  - M-C FOURNIE-ZALUSKI, "Design of orally active dual inhibitors of neutral endopeptidase angiotensin-converting enzyme with long duration action", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19960101), vol. 39, doi:10.1021/JM950783C, ISSN 0022-2623, pages 2594 - 2608, XP002150403 [X] 1,26 * Schemes 1-2; page 2603, last paragraph;; compound 4b *

DOI:   http://dx.doi.org/10.1021/jm950783c
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.